DataMeds AI Subsidiary Helomics Gains Humana Medicaid Coverage for ChemoFx Assay
DataMeds AI, Inc. (NASDAQ:MEDS) announced that its precision oncology subsidiary, Helomics Corporation, secured Medicaid coverage from Humana Inc. (NYSE:HUM) for the ChemoFx Assay in gynecologic cancers. The coverage determination applies to eligible Humana Medicaid members, including patients diagnosed with rare cancers lacking treatment guidelines, individuals undergoing initial biopsy or surgery, and those with recurrent or treatment-refractory cases.
The ChemoFx test measures how live tumor cells react to various chemotherapy drugs to assist oncologists in tailoring personalized care. The assay is billed under dedicated billing codes, and Helomics previously upgraded its laboratory automation to accommodate potential volume growth. Clinical study models in recurrent ovarian cancer indicate that assay-guided treatment selection has the potential to lower overall chemotherapy costs compared to standard empirical care.
DataMeds AI plans to publish additional data to support expanding ChemoFx testing into other difficult-to-treat cancer types. Investors should note that ChemoFx is a laboratory-developed test that has not received clearance or approval from the U.S. Food and Drug Administration, and coverage is not universal across all Humana plans.
Key points
- Helomics Corporation, a subsidiary of DataMeds AI, Inc. (NASDAQ:MEDS), received Humana Medicaid coverage for its ChemoFx Assay in gynecologic cancers.
- The coverage policy applies to specific eligible patients, including those with recurrent, treatment-refractory, or rare gynecologic cancers.
- The ChemoFx Assay helps oncologists evaluate how live tumor cells respond to chemotherapy treatments to assist in therapy selection.
- ChemoFx is a laboratory-developed test that is not cleared or approved by the U.S. Food and Drug Administration.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is the ChemoFx Assay?
The ChemoFx Assay is a chemoresponse test by Helomics Corporation that analyzes live tumor cells to determine how a patient's gynecologic cancer may respond to chemotherapy drugs.
Who is eligible for ChemoFx coverage under Humana Medicaid?
Eligible Humana Medicaid members include patients diagnosed with rare gynecologic cancers without guidelines, those undergoing initial biopsy or surgery, or patients with recurrent or treatment-refractory cases.
Is the ChemoFx Assay approved by the FDA?
No, the ChemoFx Assay is a laboratory-developed test and has not been cleared or approved by the U.S. Food and Drug Administration.